Open AccessChimeric antigen receptor T‑cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges
Author(s) -
И. В. Грибкова,
Aleksandr Zavyalov
Publication year - 2021
Publication title -
voprosy onkologii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.108
H-Index - 11
eISSN - 2949-4915
pISSN - 0507-3758
DOI - 10.37469/0507-3758-2021-67-3-350-360
Subject(s) - chimeric antigen receptor , lymphoma , medicine , cell therapy , b cell , antigen , cancer research , immunology , cd19 , refractory (planetary science) , food and drug administration , cell , t cell , oncology , pharmacology , immune system , biology , antibody , genetics , astrobiology
B-cell non-Hodgkin lymphoma (NHL) is the most common hematologic malignant neoplasm. Despite the improvement of immunochemotherapy, a significant number of patients have a refractory form of the disease. CAR T-cell therapy (therapy with T-lymphocytes with a chimeric antigen receptor (CAR)) is considered the most promising and effective therapy for overcoming chemorefractory B-cell NHL. Based on promising results from key studies, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved anti-CD19 CAR T-cell therapy for relapsing / refractory diffuse B-cell lymphoma. However, several controversial issues remain, including the optimal management of toxicity, overcoming relapses after CAR T-cell therapy, and improving the production platform of CAR T-cells. This review describes the results of recent clinical research and development, as well as the prospects for the development of CAR T-cell therapy for B-cell NHL.